Knowing that it is a BIC drug that was BTD'd just recently, I would tend to think that they will be proceeding ever so cautiously so they won't bungle again re AE's. Regardless, 113 has possible multiple indications too, not on par with pona but lesser burden than pona. Your much awaited 788 is being prepared for some main event that we don't know. Maybe they are not as concerned about the disclosure because they are not logistically prepared for the clinical trials yet, just speculating.
News 
Market Data 
Discover 
